Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
These are among the best the industry has to offer.
Vertex Pharmaceuticals is rated Sell, with fair value estimated at $398.25 versus a $530.76 share price. Read more on VRTX stock here.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Investing.com -- Vertex Pharmaceuticals (VRTX) rose about 1.2% pre-market to $560 as of Nov 3, 9:27 AM EST. It then reversed. At 12:50 PM EST the stock was at $533.24 (-3.60%), below the prior close of $553.15. Analysts mostly raised price targets, so the selloff looks like profit-taking near the 52-week high of $568.67 rather than a rejection of the results.
BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter profit of $653.
Vertex lifts 2026 revenue guidance after Q3 results. Read more here.
Vertex stock yo-yoed on its third-quarter report late Monday after earnings came up short and full-year guidance missed views.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.
Vertex Pharmaceuticals has delivered a strong multi year share price run, and the question now is whether that climb can be backed up by the cash the business is expected to generate. With a Discounted Cash Flow (DCF) framework available, the focus turns to how that share history lines up with the intrinsic value implied by its future cash streams. Over the past 5 years, Vertex Pharmaceuticals has returned 189.9% which puts real weight on whether the current valuation can be supported by the...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
If Vertex Pharmaceuticals was on your watchlist rather than in your portfolio, the return may sting. Investors who held Vertex Pharmaceuticals over the past year are up 24.3%, including dividends. That period included upbeat cystic fibrosis launches, new gene therapy approvals and a planned US$10b move into endocrinology, yet none of that was visible at the October 2025 starting line. The real question is whether early conviction around diversified gene editing and new therapies was the key...
This is the newest page. Registered accounts read further back.